There is variability in the attainment of developmental milestones in the CDKL5 disorder

Journal of Neurodevelopmental Disorders

Volumn 7, Issue 1, 2015, Pages

  Fehr, Stephanie ^a   Leonard, Helen ^a   Ho, Gladys ^c   Williams, Simon ^e   De Klerk, Nick ^a   Forbes, David ^f   Christodoulou, John ^c,d   Downs, Jenny ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b CURTIN UNIVERSITY   (Australia)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

CDKL5 disorder; Developmental disabilities; Early infantile epileptic encephalopathy; Epileptic encephalopathy

Indexed keywords

CYCLIN DEPENDENT KINASE LIKE 5 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CHILD; CONTROLLED STUDY; CYCLIN DEPENDENT KINASE LIKE 5 DISORDER; CYCLIN DEPENDENT KINASE LIKE 5 GENE; DEVELOPMENTAL DISORDER; FEMALE; GENE; GENE MUTATION; GENETIC VARIABILITY; GENETIC VARIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL CAPACITY; PRIORITY JOURNAL; SITTING; WALKING;

EID: 84983437945     PISSN: 18661947     EISSN: 18661955     Source Type: Journal    
DOI: 10.1186/1866-1955-7-2     Document Type: Article

References (44)

1. Jähn J, Caliebe A, von Spiczak S, Boor R, Stefanova I, Stephani U, et al. CDKL5 mutations as a cause of severe epilepsy in infancy: clinical and electroencephalographic long-term course in 4 patients. J Child Neurol. 2013;28:937-41.
2. Stalpers XL, Spruijt L, Yntema HG, Verrips A. Clinical phenotype of 5 females with a CDKL5 mutation. J Child Neurol. 2012;27:90-3.
3. Bahi-Buisson N, Nectoux J, Rosas-Vargas H, Milh M, Boddaert N, Girard B, et al. Key clinical features to identify girls with CDKL5 mutations. Brain. 2008;131:2647-61.
4. Fehr S, Wilson M, Downs J, Williams S, Murgia A, Sartori S, et al. The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy. Eur J Hum Genet. 2013;21:266-73.
5. Neul JL, Kaufmann WE, Glaze DG, Christodoulou J, Clarke AJ, Bahi-Buisson N, et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol. 2010;68:944-50.
6. Olson HE, Poduri A. CDKL5 mutations in early onset epilepsy: case report and review of the literature. J Pediatr Epilep. 2012;1:151-9.
7. Liang JS, Shimojima K, Takayama R, Natsume J, Shichiji M, Hirasawa K, et al. CDKL5 alterations lead to early epileptic encephalopathy in both genders. Epilepsia. 2011;52:1835-42.
8. White R, Ho G, Schmidt S, Scheffer IE, Fischer A, Yendle SC, et al. Cyclin-dependent kinase-like 5 (CDKL5) mutation screening in Rett syndrome and related disorders. Twin Res Hum Genet. 2010;13:168-78.
9. Bartnik M, Derwinska K, Gos M, Obersztyn E, Kolodziejska K, Erez A, et al. Early-onset seizures due to mosaic exonic deletions of CDKL5 in a male and two females. Genet Med. 2011;13:447-52.
10. Martínez AR, Armstrong J, Gerotina E, Fons C, Campistol J, Pineda M. CDKL5 in different atypical Rett syndrome variants: description of the first eight patients from Spain. J Pediatr Epilep. 2012;1:27-35.
11. Pini G, Bigoni S, Engerström IW, Calabrese O, Felloni B, Scusa MF, et al. Variant of Rett syndrome and CDKL5 gene: clinical and autonomic description of 10 cases. Neuropediatrics. 2013;43:37-43.
12. Weaving LS, Christodoulou J, Williamson SL, Friend KL, McKenzie OL, Archer HL, et al. Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation. Am J Hum Genet. 2004;75:1079-93.
13. Bebbington A, Anderson A, Ravine D, Fyfe S, Pineda M, de Klerk N, et al. Investigating genotype-phenotype relationships in Rett syndrome using an international dataset. Neurology. 2008;70:868-75.
14. Cuddapah VA, Pillai RB, Shekar KV, Lane JB, Motil KJ, Skinner SA, et al. Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome. J Med Genet. 2014; doi:10.1136/jmedgenet-2013-102113.
15. Hagberg B, Gillberg C. Rett Variants-rettoid phenotypes. In: Hagberg B, editor. Rett Syndrome-Clinical and Biological Aspects. London: Mac Keith Press; 1993.
16. Bertani I, Rusconi L, Bolognese F, Forlani G, Conca B, De Monte L, et al. Functional consequences of mutations in CDKL5, an X-linked gene involved in infantile spasms and mental retardation. J Biol Chem. 2006;281:32048-56.
17. Kilstrup-Nielsen C, Rusconi L, La Montanara P, Ciceri D, Bergo A, Bedogni F, et al. What we know and would like to know about CDKL5 and its involvement in epileptic encephalopathy. Neural Plast. 2012;2012:728267.
18. Castrén M, Gaily E, Tengström C, Lähdetie J, Archer H, Ala-Mello S. Epilepsy caused by CDKL5 mutations. Eur J Paediatr Neurol. 2011;15:65-9.
19. Archer HL, Evans J, Edwards S, Colley J, Newbury-Ecob R, O'Callaghan F, et al. CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients. J Med Genet. 2006;43:729-34.
20. Rademacher N, Hambrock M, Fischer U, Moser B, Ceulemans B, Lieb W, et al. Identification of a novel CDKL5 exon and pathogenic mutations in patients with severe mental retardation, early-onset seizures and Rett-like features. Neurogenetics. 2011;12:165-7.
21. Fichou Y, Bieth E, Bahi-Buisson N, Nectoux J, Girard B, Chelly J, et al. Re: CDKL5 mutations in boys with severe encephalopathy and early-onset intractable epilepsy. Neurology. 2009;73:77-8. author reply 78.
22. Yeo G, Burge CB. Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J Comput Biol. 2004;11:377-94.
23. Reese MG, Eeckman FH, Kulp D, Haussler D. Improved splice site detection in Genie. J Comput Biol. 1997;4:311-23.
24. Pertea M, Lin X, Salzberg SL. GeneSplicer: a new computational method for splice site prediction. Nucleic Acids Res. 2001;29:1185-90.
25. Desmet F-O, Hamroun D, Lalande M, Collod-Béroud G, Claustres M, Béroud C. Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res. 2009;37:e67.
26. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res. 2001;11:863-74.
27. Schwarz JM, Rodelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods. 2010;7:575-6.
28. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7:248-9.
29. Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T, Samollow PB, et al. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet. 2006;43:295-305.
30. WHO multicentre growth reference study group. WHO Motor Development Study: Windows of achievement for six gross motor development milestones. Acta Paediatr. 2006;95:86-95.
31. Artuso R, Mencarelli MA, Polli R, Sartori S, Ariani F, Pollazzon M, et al. Early-onset seizure variant of Rett syndrome: definition of the clinical diagnostic criteria. Brain Dev. 2010;32:17-24.
32. Elia M, Falco M, Ferri R, Spalletta A, Bottitta M, Calabrese G, et al. CDKL5 mutations in boys with severe encephalopathy and early-onset intractable epilepsy. Neurology. 2008;71:997-9.
33. Jansen A, Bauters M, De Rademaeker M, De Meirleir L, Froyen G, Fryns JP, et al. Epileptic encephalopathy in a boy with an interstitial deletion of Xp22 comprising the CDKL5 gene. Epilepsia. 2006;47:367.
34. Masliah-Plachon J, Auvin S, Nectoux J, Fichou Y, Chelly J, Bienvenu T. Somatic mosaicism for a CDKL5 mutation as an epileptic encephalopathy in males. Am J Med Genet. 2010;152A:2110-1. doi:10.1002/ajmg.a.33037.
35. Melani F, Mei D, Pisano T, Savasta S, Franzoni E, Ferrari A, et al. CDKL5 gene-related epileptic encephalopathy: electroclinical findings in the first year of life. Dev Med Child Neurol. 2011;53:354-60.
36. Mirzaa GM, Paciorkowski AR, Marsh ED, Berry-Kravis EM, Medne L, Alkhateeb A, et al. CDKL5 and ARX mutations in males with early-onset epilepsy. Pediatr Neurol. 2013;48:367-77.
37. Nishimura A, Takano T, Mizuguchi T, Saitsu H, Takeuchi Y, Matsumoto N. CDKL5 disruption by t(X;18) in a girl with West syndrome. Clin Genet. 2008;74:288-90.
38. Sartori S, Di Rosa G, Polli R, Bettella E, Tricomi G, Tortorella G, et al. A novel CDKL5 mutation in a 47, XXY boy with the early-onset seizure variant of Rett syndrome. Am J Med Genet. 2009;149A:232-6.
39. Chen QA, Zhu YC, Yu J, Miao S, Zheng J, Xu L, et al. CDKL5, a protein associated with Rett syndrome, regulates neuronal morphogenesis via Rac1 signaling. J Neurosci. 2010;30:12777-86.
40. Ricciardi S, Ungaro F, Hambrock M, Rademacher N, Stefanelli G, Brambilla D, et al. CDKL5 ensures excitatory synapse stability by reinforcing NGL-1-PSD95 interaction in the postsynaptic compartment and is impaired in patient iPSC-derived neurons. Nat Cell Biol. 2012;14:911-23.
41. Valli E, Trazzi S, Fuchs C, Erriquez D, Bartesaghi R, Perini G, et al. CDKL5, a novel MYCN-repressed gene, blocks cell cycle and promotes differentiation of neuronal cells. Biochim Biophys Acta. 2012;1819:1173-85.
42. Nardou R, Ferrari DC, Ben-Ari Y. Mechanisms and effects of seizures in the immature brain. Semin Fetal Neonatal Med. 2013;18:175-84.
43. Bahi-Buisson N, Villeneuve N, Caietta E, Jacquette A, Maurey H, Matthijs G, et al. Recurrent mutations in the CDKL5 gene: genotype-phenotype relationships. Am J Med Genet A. 2012;158A:1612-9.
44. Rusconi L, Salvatoni L, Giudici L, Bertani I, Kilstrup-Nielsen C, Broccoli V, et al. CDKL5 expression is modulated during neuronal development and its subcellular distribution is tightly regulated by the C-terminal tail. J Biol Chem. 2008;283:30101-11.